STAT Plus: Sage’s new antidepressant faces major setback in new study
APSTOCK
The medication, which aimed to treat depression more rapidly than existing drugs, failed its first large study in patients in major depression.
Suscribirse a:
Enviar comentarios (Atom)
No hay comentarios:
Publicar un comentario